

Point-by-point response to reviewers

Manuscript NO: 70886

Name of journal: World Journal of Psychiatry

Title: Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness

Response to Editorial Office:

We would like to thank the editors and the reviewers for their comments on our paper. We have looked carefully on your remarks and made the appropriate changes, which helped to enhance the quality of the submitted manuscript. We hope that the corrections made will meet the scientific standards of the journal and the reviewers.

Our respond step by step to the questions/comments:

1. Some data upload in Table 1 is incomplete, cannot know whether the data is correct.

Answer: We are not completely sure which data the reviewer refers to be incomplete in table 1. For the calculation of Duration of untreated psychosis (DUP), there were available data for only 65 patients in total (instead of the total included of 144). This is commented now better in the "Results" section under "Subjects". When it comes to the other parameters presented in table 1, we have now added more information specifying the numbers of participants with available data for analysis, so that the readers obtain a complete picture of the total number of patients with available data. This information can also be found in the "Results" section under "Subjects". We hope that this answers to the reviewer's question.

2. The sample size of selected data is small and lasts for a long time, and the final result may be affected by sample shedding. Therefore, a larger sample size can be selected at the beginning; In addition, there was no clear explanation as to whether the patients in the selected samples were taking medication as required from the beginning to the end.

Answer: The sample size was defined out of power estimates, and these data can be found in the main article of BeSt InTro study, which is referred to in the text. About the second part of the comment, it is true that not all patients took their antipsychotic medication as required during the complete follow-up period. This is common in drug trials, and is found in all antipsychotic drug trials. To address this issue, we calculated a variable shown in Table 1, called "Duration of AP treatment", and we found no significant difference among the three response groups. Please let us know if you require more specifications about these issues.

3. Further research is needed to determine whether the results hold true for all races.

Answer: Our study was conducted in Norway, where the majority of the population is white Europeans, and indeed most of the included patients belonged to this group (88%). Our research results can not be generalizable to Chinese or African populations for example, and we absolutely agree that more research is needed to address this issue. We acknowledge that this is a limitation of the study and we have added a comment on that at the end of the "Discussion" section.